Transcatheter aortic valve replacement: focus on sex-related differences in outcomes.
Transcatheter aortic valve replacement (TAVR) has transformed the management of severe aortic stenosis for high-risk and inoperable patients. The 10-year experience in Europe has proven the technology to be safe and effective in select populations. The PARTNER trial, the first prospective, randomized, controlled trial for TAVR, showed the technology to be superior to medical management for inoperable patients and equivalent to surgical aortic valve replacement for high-risk patients. Research in cardiovascular medicine has been dominated by studies on the male sex, due to the incidence of the disease process and partly due to historic predominance of male subjects in research studies. Alternatively, TAVR studies focused on high-risk and inoperable patients who are equally distributed by sex. Although sex-related differences are apparent in their baseline characteristics, outcomes have been mixed, with evidence suggesting that female patients may have a mortality advantage with TAVR. Herein we review the TAVR procedure and devices currently available and focus our discussion on outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis.
Division of Cardiovascular Medicine, School of Medicine, University of Louisville, Louisville, KY, USA.
Michael P
MP
Flaherty
Kendra J
KJ
Grubb
D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012727:Sex Characteristics; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects / Q000401:mortality / Q000639:trends*; D016896:Treatment Outcome